Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749813 | 1.00 | CRBN (0.36) | CRBNTSHRPOLBOR51E2TACR1 | |
| SCHEMBL2603211 | 1.00 | CRBN (0.36) | CRBNTSHRPOLBOR51E2TACR1 | |
| SCHEMBL14749800 | 0.88 | OR51E2 (0.38) | CRBNTSHROR51E2FKBP5 | |
| SCHEMBL10730399 | 0.88 | OR51E2 (0.38) | CRBNTSHROR51E2FKBP5 | |
| SCHEMBL27259620 | 0.83 | CRBN (0.33) | CRBNTSHRPOLBIRAK4 | |
| SCHEMBL4455443 | 0.81 | CRBN (0.40) | CRBNPOLBOR51E2FKBP5 | |
| SCHEMBL14749801 | 0.81 | CRBN (0.40) | CRBNPOLBOR51E2FKBP5 | |
| SCHEMBL21846797 | 0.80 | HCAR2 (0.32) | CRBNTSHRIRAK4 | |
| SCHEMBL14749811 | 0.77 | — | — | |
| SCHEMBL6155366 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2022106857-A1 | MALT-1 MODULATORS | Exscientia Limited (GB) | 2022-05-27 | — | — | WO | disclosed |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | SPV THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2020247496-A1 | 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS | ARCUS BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | CRBN 1/4885TSHR 2599/4885POLB 3883/4885 |
| US-20220056037-A1 | CYCLIN-DEPENDENT KINASE INHIBITORS | CDK2, CDK1, CCNK | CRBN 792/4885TSHR 3124/4885POLB 679/4885 |
| US-20130225564-A1 | HALOARYL SUBSTITUTED AMINOPURINES, COMPOSITIONS THEREOF,AND METHODS OF TREATMENT THEREWITH | TPMT, MGMT, HPRT1 | CRBN 1135/4885TSHR 2299/4885POLB 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.